These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37489294)

  • 21. 372 kb microdeletion in 18q12.3 causing SETBP1 haploinsufficiency associated with mild mental retardation and expressive speech impairment.
    Marseglia G; Scordo MR; Pescucci C; Nannetti G; Biagini E; Scandurra V; Gerundino F; Magi A; Benelli M; Torricelli F
    Eur J Med Genet; 2012 Mar; 55(3):216-21. PubMed ID: 22333924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unusual neuroradiological features in Schinzel-Giedion syndrome: a novel case.
    Lestner JM; Chong WK; Offiiah A; Kefas J; Vandersteen AM
    Clin Dysmorphol; 2012 Jul; 21(3):152-154. PubMed ID: 22473152
    [No Abstract]   [Full Text] [Related]  

  • 23. Somatic SETBP1 mutations in myeloid neoplasms.
    Makishima H
    Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.
    Torrejón B; Cristóbal I; Caramés C; Prieto-Potín I; Chamizo C; Santos A; Sanz-Alvarez M; Serna-Blasco R; Luque M; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    World J Surg; 2018 Nov; 42(11):3771-3778. PubMed ID: 29796729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatic SETBP1 mutations in myeloid malignancies.
    Makishima H; Yoshida K; Nguyen N; Przychodzen B; Sanada M; Okuno Y; Ng KP; Gudmundsson KO; Vishwakarma BA; Jerez A; Gomez-Segui I; Takahashi M; Shiraishi Y; Nagata Y; Guinta K; Mori H; Sekeres MA; Chiba K; Tanaka H; Muramatsu H; Sakaguchi H; Paquette RL; McDevitt MA; Kojima S; Saunthararajah Y; Miyano S; Shih LY; Du Y; Ogawa S; Maciejewski JP
    Nat Genet; 2013 Aug; 45(8):942-6. PubMed ID: 23832012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of
    Leonardi E; Bettella E; Pelizza MF; Aspromonte MC; Polli R; Boniver C; Sartori S; Milani D; Murgia A
    Front Neurol; 2020; 11():593446. PubMed ID: 33391157
    [No Abstract]   [Full Text] [Related]  

  • 27. Identification of eight novel NSD1 mutations in Sotos syndrome.
    Kamimura J; Endo Y; Kurotaki N; Kinoshita A; Miyake N; Shimokawa O; Harada N; Visser R; Ohashi H; Miyakawa K; Gerritsen J; Innes AM; Lagace L; Frydman M; Okamoto N; Puttinger R; Raskin S; Resic B; Culic V; Yoshiura K; Ohta T; Kishino T; Ishikawa M; Niikawa N; Matsumoto N
    J Med Genet; 2003 Nov; 40(11):e126. PubMed ID: 14627693
    [No Abstract]   [Full Text] [Related]  

  • 28. Identification of a novel de novo mutation of SETBP1 and new findings of SETBP1 in tumorgenesis.
    Wang H; Gao Y; Qin L; Zhang M; Shi W; Feng Z; Guo L; Zhu B; Liao S
    Orphanet J Rare Dis; 2023 May; 18(1):107. PubMed ID: 37150818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel SETBP1 mutation in a chinese family with intellectual disability.
    Wang L; Wang XD; Yang B; Wang XM; Peng YQ; Tan HJ; Xiao HM
    BMC Med Genomics; 2023 Oct; 16(1):233. PubMed ID: 37798664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.
    Piazza R; Valletta S; Winkelmann N; Redaelli S; Spinelli R; Pirola A; Antolini L; Mologni L; Donadoni C; Papaemmanuil E; Schnittger S; Kim DW; Boultwood J; Rossi F; Gaipa G; De Martini GP; di Celle PF; Jang HG; Fantin V; Bignell GR; Magistroni V; Haferlach T; Pogliani EM; Campbell PJ; Chase AJ; Tapper WJ; Cross NC; Gambacorti-Passerini C
    Nat Genet; 2013 Jan; 45(1):18-24. PubMed ID: 23222956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
    Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
    Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.
    Fernandez-Mercado M; Pellagatti A; Di Genua C; Larrayoz MJ; Winkelmann N; Aranaz P; Burns A; Schuh A; Calasanz MJ; Cross NC; Boultwood J
    Br J Haematol; 2013 Oct; 163(2):235-9. PubMed ID: 23889083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refractory sacrococcygeal germ cell tumor in Schinzel-Giedion syndrome.
    Kishimoto K; Kobayashi R; Yonemaru N; Yamamoto H; Tsujioka T; Sano H; Suzuki D; Yasuda K; Suzuki M; Ando A; Tonoki H; Iizuka S; Uetake K; Kobayashi K
    J Pediatr Hematol Oncol; 2015 May; 37(4):e238-41. PubMed ID: 25171454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.
    Shou LH; Cao D; Dong XH; Fang Q; Wu Y; Zhang Y; Fei JP; Xu BL
    PLoS One; 2017; 12(2):e0171608. PubMed ID: 28158286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
    Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
    Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Yao XY; Zhou JD; Yang J; Zhang W; Ma JC; Wen XM; Yao DM; Xu ZJ; Wu DH; He PF; Qian J; Lin J
    Pathol Res Pract; 2018 May; 214(5):706-712. PubMed ID: 29549983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia.
    Cristóbal I; Blanco FJ; Garcia-Orti L; Marcotegui N; Vicente C; Rifon J; Novo FJ; Bandres E; Calasanz MJ; Bernabeu C; Odero MD
    Blood; 2010 Jan; 115(3):615-25. PubMed ID: 19965692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Unusual facies with delayed development and multiple malformations in a 14-month-old boy].
    Lu T; Wang Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2017 Aug; 19(8):921-925. PubMed ID: 28774369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies.
    Winkelmann N; Schäfer V; Rinke J; Kaiser A; Ernst P; Scholl S; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2511-2519. PubMed ID: 28913558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
    Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.